PharmaShots Weekly Snapshots (July 12 – 16, 2021)

 PharmaShots Weekly Snapshots (July 12 – 16, 2021)

Eli Lilly Signs an Agreement with Banner Alzheimer’s Institute to Evaluate Donanemab in P-III TRAILBLAZER-ALZ 3 Trial for Alzheimer’s Disease

Published: July 16, 2021 | Tags: Eli Lilly, Banner Alzheimer’s Institute, Donanemab, P-III, TRAILBLAZER-ALZ 3 Trial, Alzheimer Disease

AcelRx Signs a License Agreement with Aguettant to Commercialize Dzuveo in EU and for Two Pre-Filled Syringe Products in US

Published: July 16, 2021 | Tags: AcelRx, License Agreement, Aguettant, Dzuveo, EU, Pre-Filled Syringe Products, US

Bio-Thera Reports First Patient Dosing in P-III Study for BAT2206 Proposed Biosimilar of Stelara (ustekinumab)

Published: July 16, 2021 | Tags: Bio-Thera, P-III, BAT2206, Proposed Biosimilar, Stelara, Ustekinumab

Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Published: July 16, 2021 | Tags: Vir, P-II, MARCH Trial, VIR-2218, VIR-3434, Functional Cure Regimen, Chronic Hepatitis B Virus Infection

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study for Generalized Myasthenia Gravis

Published: July 16, 2021 | Tags: Alexion, Ultomiris, ravulizumab-cwvz, P-III, Study, Generalized Myasthenia Gravis

Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease

Published: July 16, 2021 | Tags: Ipsen, License Agreement, IRLAB, Mesdopetam, Parkinson Disease

Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics to Correct RNA Expression

Published: July 15, 2021 | Tags: Skyhawk, Aragen, Develop, Novel Small Molecule Therapeutics

Heat Biologics Signs a Research License Agreement with ProBioGen for Transposase System and Suspension HEK293 Cell Line

Published: July 15, 2021 | Tags: Heat Biologics, ProBioGen, Transposase System, Suspension, HEK293 Cell Line

Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM

Published: July 15, 2021 | Tags: Johnson & Johnson, Single-Shot COVID-19 Vaccine, P-I/IIa, Sub-Study, COVID 19, NEJM

Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NEJM

Published: July 15, 2021 | Tags: Novartis, Incyte, Jakafi, ruxolitinib, P-III, REACH3 Study, Chronic Graft-Versus-Host Disease, NEJM

Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis

Published: July 15, 2021 | Tags: Galapagos, GLPG3667, P-Ib, Study, Psoriasis

Eli Lilly to Acquire Protomer Technologies for ~$1B

Published: July 15, 2021 | Tags: Eli Lilly, Acquire, Protomer Technologies, ~$1B

Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Published: July 14, 2021 | Tags: Caribou, First Patient Dosing, P-I, ANTLER Trial, CB-010, B- Cell Non-Hodgkin Lymphoma

Strongbridge Reports Results of Post Hoc Analyses from a One Year HYPHOP Study of Keveyis (dichlorphenamide) to Treat Primary Periodic Paralysis

Published: July 14, 2021 | Tags: Strongbridge, Post Hoc Analyses, One Year, HYPHOP Study, Keveyis, dichlorphenamide, Primary Periodic Paralysis

Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells

Published: July 14, 2021 | Tags: Astellas, License Agreement, ExCellThera, In Vitro, UM171, Pluripotent Stem Cells

Ionis Signs an Exclusive WW License Agreement with Bicycle to Develop Targeted Oligonucleotide Therapeutics Using TfR1 Bicycle Technology

Published: July 14, 2021 | Tags: Ionis, Exclusive License Agreement, Bicycle, Targeted Oligonucleotide Therapeutics, TfR1 Bicycle Technology

Hologic Receives CE Mark to Use Saliva Samples with Aptima SARS-CoV-2 Test in EU

Published: July 14, 2021 | Tags: Hologic, CE Mark, Saliva Samples, Aptima SARS-CoV-2 Test, EU

Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH

Published: July 14, 2021 | Tags: Hepion, CRV431, P-IIa, AMBITION Trial, NASH

Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae

Published: July 13, 2021 | Tags: Astellas, Affinivax, ASP3772, P-II, Study, Streptococcus pneumoniae

Hutchmed Reports First Commercial Sale of Orpathys (savolitinib) in China

Published: July 13, 2021 | Tags: Hutchmed, First Commercial Sale, Orpathys, savolitinib, China

Janssen’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone Receive the US FDA’s Approval to Treat Patients with Multiple Myeloma

Published: July 13, 2021 | Tags: Janssen, Darzalex Faspro, daratumumab, hyaluronidase-fihj, Pomalidomide, Dexamethasone, US, FDA, Approval, Multiple Myeloma

Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

Published: July 13, 2021 | Tags: Menagen, Commercialization Agreement, CKD, Biosimilar Darbepotein Alfa

Biogen Signs a License Agreement with Innocare for Orelabrutinib to Treat Multiple Sclerosis

Published: July 13, 2021 | Tags: Biogen, License Agreement, Innocare, Orelabrutinib, Multiple Sclerosis

Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B

Published: July 13, 2021 | Tags: Novo Nordisk, Acquire, Prothena, ATTR Amyloidosis Programme, $1.2B

Janssen Presents Three-Year Data of Stelara (ustekinumab) in P-lll UNIFI LTE Study for the Treatment of Moderately to Severely Active Ulcerative Colitis at ECCO

Published: July 12, 2021 | Tags: Janssen, Stelara, ustekinumab, P-lll, UNIFI LTE Study, Active Ulcerative Colitis

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

Published: July 12, 2021 | Tags: Galapagos, P-III, SELECTION Trials, Filgotinib, Ulcerative Colitis, UC

Innovent Reports First Patient Dosing in P-I CIBI323A101 Study of IBI323 to Treat Advanced Malignant Tumors

Published: July 12, 2021 | Tags: Innovent, P-I, CIBI323A101 Study, IBI323, Advanced Malignant Tumors

Astellas and Seagen’s Padcev (enfortumab vedotin-ejfv) Receive the US FDA’s Full Approval and Expands Indication for Patients with Locally Advanced or Metastatic Urothelial Cancer

Published: July 12, 2021 | Tags: Astellas, Seagen, Padcev, enfortumab vedotin-ejfv, US, FDA, Regular Approval, Locally Advanced, Metastatic Urothelial Cancer

Takeda Presents Results of Takhzyro (lanadelumab) in P-III HELP Study Open-Label Extension to Treat Hereditary Angioedema Attacks at EAACI 2021

Published: July 12, 2021 | Tags: Takeda, Takhzyro, lanadelumab, P-III, HELP Study, Open-Label Extension, Hereditary Angioedema Attacks, EAACI 2021

Bayer’s Kerendia (finerenone) Receives the US FDA’s Approval for the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes

Published: July 12, 2021 | Tags: Bayer, Kerendia, finerenone, US, FDA, Approval, Chronic Kidney Disease, Type 2 Diabetes

Related Post: PharmaShots Weekly Snapshots (July 05 – 09, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post